# Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

> **NCT07216248** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** relugolix + ARPI
- **DRUG:** Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
- **DRUG:** relugolix or androgen deprivation therapy (ADT) + ARPI
- **DRUG:** relugolix + ARPI.

## Key facts

- **NCT ID:** NCT07216248
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2030-10
- **Final completion:** 2031-10
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216248, "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07216248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*